Adlai Nortye Ltd American Depositary Shares (ANL) Stock Price, Quote & News

Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the t...

Industry: Biotechnology

Sector: Healthcare

Phone: 848 230 7430

Website: www.adlainortye.com

Address:

Ugland House, PO Box 309, Grand Cayman, Cayman Islands

Nothere2023 Mar. 12 at 3:50 PM

$ANL Break down here can straight pull down to $3.5

0 · Reply

Nothere2023 Mar. 11 at 4:15 PM

$ANL RSI cooled off , chart looks good , should be back above 10+

0 · Reply

Nothere2023 Mar. 10 at 6:25 PM

$ANL This is set up very nicely to fly 🚀🚀🚀

0 · Reply

Alt_Fuel Mar. 10 at 6:20 AM

$VSTM Specific details on exact conferences and presentation dates for updated GFH375 (VS-7375) data in 2026 have not yet been publicly announced by GenFleet Therapeutics or its partner Verastem Oncology... $ANL ... $ERAS ... $RVMD However, Verastem has outlined plans to report an interim safety and efficacy update from the ongoing U.S.-based Phase 1/2 trial (VS-7375-101) in the first half of 2026, with a more comprehensive update in the second half of 2026. These timelines could align with major oncology conferences, such as: AACR Annual Meeting: April 17-22, 2026 (San Diego, CA). ASCO Annual Meeting: May 29-June 2, 2026 (Chicago, IL). Other global oncology events later in 2026 where data might be presented include ESMO Congress ( September ?) or the World Conference on Lung Cancer ( September ?)... GenFleet - intends to share updates across indications like NSCLC, PDAC, and other KRAS G12D-mutant solid tumors at international events throughout 2026 - no specific dates confirmed...

0 · Reply

Alt_Fuel Mar. 5 at 7:21 PM

$VSTM Jefferies reiterates Verastem $VSTM stock rating on launch progress - 03/05/2026, 10:54 AM https://www.investing.com/news/analyst-ratings/jefferies-reiterates-verastem-stock-rating-on-launch-progress-93CH-4544702 Next 6 to 12 months will be interesting ... $ERAS $ANL $RVMD

0 · Reply

Godwins26 Feb. 25 at 11:07 PM

Watchlist 🚀 $HCTI $TCGL $ANL

0 · Reply

BillionerOfKing Feb. 20 at 2:48 AM

$ANL Current Stock Price: $9.86

0 · Reply

OfficialStocktwitsUser Feb. 18 at 10:06 PM

$ANL RSI: 78.15, MACD: 1.9246 Vol: 3.30, MA20: 7.53, MA50: 3.90 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

topstockalerts Feb. 18 at 7:50 PM

$ANL Interesting spot for a momentum swing 💡. Price is holding strength. Buyers are clearly engaged.

0 · Reply

johnjaha Feb. 18 at 7:44 PM

$ANL $LNKS $SGN Blocked for Spamming tickers. Only one ticker. SGN.

0 · Reply

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

Feb 3, 2026, 7:00 AM EST - 5 weeks ago

Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

Dec 29, 2025, 6:00 AM EST - 2 months ago

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

Oct 13, 2025, 11:07 PM EDT - 5 months ago

Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

May 23, 2024, 9:03 PM EDT - 1 year ago

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

May 22, 2024, 8:00 AM EDT - 1 year ago

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

Mar 29, 2024, 6:00 AM EDT - 2 years ago

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Nov 17, 2023, 7:30 AM EST - 2 years ago

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

Oct 23, 2023, 8:12 AM EDT - 2 years ago

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

Oct 13, 2023, 8:00 AM EDT - 2 years ago

Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles

Oct 3, 2023, 12:05 PM EDT - 2 years ago

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

Sep 30, 2023, 3:30 AM EDT - 2 years ago

U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline

BIRK KHIW LRE VSME

Sep 29, 2023, 2:46 AM EDT - 2 years ago

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

Sep 3, 2023, 10:45 AM EDT - 2 years ago

U.S. IPO Weekly Recap: August Wraps Up With 1 Nano-Cap

ABNB ARM CART IPO IPOS SNOW

Aug 12, 2023, 6:00 AM EDT - 2 years ago

U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices

NRXS NWGL VFS

Aug 11, 2023, 2:16 PM EDT - 2 years ago

IPO Update: Adlai Nortye Readies $72 Million U.S. IPO

Aug 11, 2023, 7:05 AM EDT - 2 years ago

Cancer treatment company Adlai Nortye sets terms in IPO

Jul 31, 2023, 6:17 PM EDT - 2 years ago

Adlai Nortye Ltd. Begins U.S. IPO Rollout

Nothere2023 Mar. 12 at 3:50 PM

$ANL Break down here can straight pull down to $3.5

0 · Reply

Nothere2023 Mar. 11 at 4:15 PM

$ANL RSI cooled off , chart looks good , should be back above 10+

0 · Reply

Nothere2023 Mar. 10 at 6:25 PM

$ANL This is set up very nicely to fly 🚀🚀🚀

0 · Reply

Alt_Fuel Mar. 10 at 6:20 AM

0 · Reply

Alt_Fuel Mar. 5 at 7:21 PM

0 · Reply

Godwins26 Feb. 25 at 11:07 PM

Watchlist 🚀 $HCTI $TCGL $ANL

0 · Reply

BillionerOfKing Feb. 20 at 2:48 AM

$ANL Current Stock Price: $9.86

0 · Reply

OfficialStocktwitsUser Feb. 18 at 10:06 PM

0 · Reply

topstockalerts Feb. 18 at 7:50 PM

$ANL Interesting spot for a momentum swing 💡. Price is holding strength. Buyers are clearly engaged.

0 · Reply

johnjaha Feb. 18 at 7:44 PM

$ANL $LNKS $SGN Blocked for Spamming tickers. Only one ticker. SGN.

0 · Reply

RubenWashinton240 Feb. 18 at 12:46 PM

$ANL Energy infrastructure exposure tied to LNG demand cycles.

0 · Reply

Godwins26 Feb. 17 at 1:32 AM

We are open!!! 😊 $RIME $TCGL $ANL

2 · Reply

Gtrading1234 Feb. 15 at 5:47 AM

$ANL

0 · Reply

Godwins26 Feb. 14 at 12:22 AM

Lottery 🎰 Watchlist 🤑 $RIME $ANL $TCGL

0 · Reply

Paraboljoker Feb. 13 at 9:43 PM

$JDZG Usually when i have a ticker on my radar it’s a leading indicator to go parabolic sooner than way later👀 make sure to follow @Paraboljoker for more 200% Wins/explosive upcoming swingplays like $JDZG 🔥🃏 + see my bio 🔗 Nanocaps n pennies going to dollarz these days🤙🏻 💸 ! $GITS $BNAI $LNKS $ANL

0 · Reply

BillionerOfKing Feb. 12 at 3:35 PM

$ANL Current Stock Price: $9.78

0 · Reply

RicardoCastro251 Feb. 11 at 5:23 PM

$ANL Anl or unknown; not a standard ticker; speculative.

0 · Reply

Godwins26 Feb. 11 at 6:29 AM

$QNCX $TCGL $ROIV $ANL $BNAI

0 · Reply

Godwins26 Feb. 11 at 6:28 AM

Lottery 🎰 Watchlist $QNCX is this the next lottery play and will you be rich 🤑 $TCGL $ROIV $ANL $BNAI

1 · Reply

Godwins26 Feb. 11 at 4:59 AM

Lottery 🎰 Watchlist 🚀 $QNCX can we see $430? 🤔 $TCGL $ANL

2 · Reply

Godwins26 Feb. 10 at 11:46 PM

Watchlist 🚀 $QNCX can it hit $430 $TCGL $BNAI $ANL

1 · Reply

Godwins26 Feb. 10 at 7:49 PM

Watchlist 😊 $QNCX we doing a 500% $TCGL $ANL $SMX

0 · Reply

Market Cap	57.20M
Revenue (ttm)	0.00
Net Income (ttm)	-51.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.03

Volume	846
Avg Vol	19,594
Day's Range	N/A - N/A
Shares Out	36.90M
Stochastic %K	21%
Beta	-0.83
Analysts	Hold
Price Target	$9.00